The present invention relates to [3 (2 cyclopentyl 2 hydroxy 2 crystalline phenyl) ethoxy] methyl bromide 1 1 3-azabicyclo [2,2,2] octane I and its preparation and use. It involves the field of medical technology. There is no published report on the crystal type I of the compounds at home and abroad, as well as their preparation and uses. The crystal type I of the compound and its preparation method and use are provided: the XRPD characteristic peak of the crystal type I of the compound is shown in figure 1. Preparation method: adding acetone to compound materials; heating and stirring to fully dissolve solid; continue to stir hot filtration, the filtrate was collected under heating and evaporation of the solvent to the filtrate; adding ethyl ether, stirring the solution mixing, solid precipitation, suspension static filtration; solid under heating vacuum drying the suspension; mixed white solid obtained in ethyl acetate after filtration; collection of solid. The application of compound crystal I in the preparation of selective anticholinergic drugs.
【技术实现步骤摘要】
化合物的晶型I及其制备方法和用途
本专利技术涉及医药
,具体地说是提供选择性抗胆碱能药——3-[(2-环戊基-2-羟基-2-苯基)乙氧基]-1-甲基-溴化-1-氮杂双环[2,2,2]辛烷的晶型I及其制备方法和用途。
技术介绍
3-[(2-环戊基-2-羟基-2-苯基)乙氧基]-1-甲基-溴化-1-氮杂双环[2,2,2]辛烷为选择性抗胆碱能药,对M受体有明显的选择性(对M2受体无明显作用)。其通过拮抗迷走神经释放的递质乙酰胆碱而抑制迷走神经的反射。药效学试验表明:3-[(2-环戊基-2-羟基-2-苯基)乙氧基]-1-甲基-溴化-1-氮杂双环[2,2,2]辛烷具有明显的抗过敏、抗炎、止痒作用,还能降低毛细血管通透性。3-[(2-环戊基-2-羟基-2-苯基)乙氧基]-1-甲基-溴化-1-氮杂双环[2,2,2]辛烷能抑制致敏小鼠抗原攻击引起的气道炎症、气道重塑和气道高反应,其作用机制与调节Th1/Th2细胞的平衡、减少细胞因子和嗜酸性粒细胞趋化因子表达有关。3-[(2-环戊基-2-羟基-2-苯基)乙氧基]-1-甲基-溴化-1-氮杂双环[2,2,2]辛烷是一种季铵盐,它穿过鼻粘膜、胃肠道和血脑屏障的能力极小,导致全身性抗胆碱能作用很低(包括精神、眼睛、心血管和胃肠道作用)。药理毒理研究结果表明:3-[(2-环戊基-2-羟基-2-苯基)乙氧基]-1-甲基-溴化-1-氮杂双环[2,2,2]辛烷毒性很低,临床推荐使用剂量范围内的安全系数较大。I、II和III期临床试验结果表明:3-[(2-环戊基-2-羟基-2-苯基)乙氧基]-1-甲基-溴化-1-氮杂双环[2,2,2] ...
【技术保护点】
3‑[(2‑环戊基‑2‑羟基‑2‑苯基)乙氧基]‑1‑甲基‑溴化‑1‑氮杂双环[2,2,2]辛烷的晶型I,其特征在于,具有如下在粉末X‑射线衍射法中测定的在如下位置的衍射信号:(2θ±0.2度):
【技术特征摘要】
1.3-[(2-环戊基-2-羟基-2-苯基)乙氧基]-1-甲基-溴化-1-氮杂双环[2,2,2]辛烷的晶型I,其特征在于,具有如下在粉末X-射线衍射法中测定的在如下位置的衍射信号:(2θ±0.2度):峰角度强度强度%编号2θ°计数%14.958843.226.950737.339.875455.4410.976656.3513.915011.0614.728921.3715.614810.9817.119514.3917.642331.11018.417913.21119.643431.91220.218613.71321.952238.41424.51360100.01525.035025.71628.739829.31730.015611.51831.224818.21931.516912.42033.11229.02135.017713.02.权利要求1的3-[(2-环戊基-2-羟基-2-苯基)乙氧基]-1-甲基-溴化-1-氮杂双环[2,2,2]辛烷的晶型I,其特征为,在使用DSC进行热分析时,在178±2℃出现吸热峰。3.如权利要求1或2中任一项的3-[(2-环戊基-2-羟基-2-苯基)乙氧基]-1-甲基-溴化-1-氮杂双环[2,2,2]辛烷的晶型I的制备方法,其特征在于,a)向3-[(2-环戊基-2-羟基-2-苯基)乙氧基]-1-甲基-溴化-1-氮杂双环[2,2,2]辛烷原料加入丙酮;b)加热搅拌使固体充分溶解;c)在加热下继续搅拌后趁热过滤,收集滤液,对滤液蒸发溶剂;d)加入乙醚,搅拌使...
【专利技术属性】
技术研发人员:赵书强,于文占,
申请(专利权)人:银谷制药有限责任公司,
类型:发明
国别省市:北京,11
还没有人留言评论。发表了对其他浏览者有用的留言会获得科技券。